Gastroesophageal Junction Adenocarcinoma clinical trials at UC Davis
1 research study open to eligible people
A Study of the Experimental Combination of Olaparib and Ramucirumab For Metastatic Gastric or Gastroesophageal Junction Cancer
open to eligible people ages 18 years and up
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab alone.
Sacramento, California and other locations